Early control of low-density lipoprotein cholesterol (LDL-C) is crucial for reducing the progress of cardiovascular disease. However, its additional role to the risk of primary osteoporosis in men with coronary heart disease was inconclusive. Our study aims to determine the association of LDL-C and its trajectories for osteoporosis risk in the middle-aged and aged men of China.
The retrospective cohort study of 1546 men aged 69.74 ± 11.30 years conducted in Beijing, China from 2015 to 2022. And the incidence of primary osteoporosis was annually recorded. LDL-C trajectories were further identified by latent class growth model using repeated measurements of LDL-C. The association of baseline LDL-C for osteoporosis was estimated using hazard ratio (HR) with 95% CI in Cox proportional hazard model, while mean level and trajectories of LDL-C for osteoporosis were evaluated using odds ratio (OR) with 95% CI in logistic regression model.
During the median 6.2-year follow-up period, 70 men developed primary osteoporosis. The higher level of baseline LDL-C (HR = 1.539, 95% CI: 1.012–2.342) and mean LDL-C (OR = 2.190, 95% CI: 1.443–3.324) were associated with higher risk of osteoporosis in men with coronary heart disease after adjusted for covariates. Compared with those in the LDL-C trajectory of low-stable decrease, participants with medium-fluctuant trajectory, whose longitudinal LDL-C started with a medium LDL-C level and appeared an increase and then decrease, were negatively associated with osteoporosis risk (OR = 2.451, 95% CI: 1.152–5.216). And participants with initially high LDL-C level and then a rapid decrease demonstrated a tendency towards reduced risk (OR = 0.718, 95% CI: 0.212–2.437).
Elevated LDL-C level and its long-term fluctuation may increase the risk of primary osteoporosis in men. Early controlling a stable level of LDL-C is also essential for bone health.
Oliva M, Muñoz-Aguirre M, Kim-Hellmuth S, et al. The impact of sex on gene expression across human tissues. Science 2020; 369: eaba3066.
Holven KB, Roeters van LJ. Sex differences in lipids: a life course approach. Atherosclerosis 2023; 384: 117270.
Wang L, Yu W, Yin X, et al. Prevalence of osteoporosis and fracture in China: the China Osteoporosis Prevalence Study. JAMA Netw Open 2021; 4: e2121106.
Vilaca T, Eastell R, Schini M. Osteoporosis in men. Lancet Diabetes Endocrinol 2022; 10: 273−283.
Rinonapoli G, Ruggiero C, Meccariello L, et al. Osteoporosis in men: a review of an underestimated bone condition. Int J Mol Sci 2021; 22: 2105.
Hu X, Ma S, Chen L, et al. Association between osteoporosis and cardiovascular disease in elderly people: evidence from a retrospective study. PeerJ 2023; 11: e16546.
Hill MA, Yang Y, Zhang L, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism 2021; 119: 154766.
Conte C, Epstein S, Napoli N. Insulin resistance and bone: a biological partnership. Acta Diabetol 2018; 55: 305−314.
Cherny SS, Freidin MB, Williams FMK, et al. The analysis of causal relationships between blood lipid levels and BMD. PLoS One 2019; 14: e0212464.
Zheng J, Brion MJ, Kemp JP, et al. The effect of plasma lipids and lipid-lowering interventions on bone mineral density: a Mendelian randomization study. J Bone Miner Res 2020; 35: 1224−1235.
Li GH, Cheung CL, Au PC, et al. Positive effects of low LDL-C and statins on bone mineral density: an integrated epidemiological observation analysis and Mendelian randomization study. Int J Epidemiol 2020; 49: 1221−1235.
Zhao H, Li Y, Zhang M, et al. Blood lipid levels in patients with osteopenia and osteoporosis: a systematic review and meta-analysis. J Bone Miner Metab 2021; 39: 510−520.
Zhang Q, Zhou J, Wang Q, et al. Association between bone mineral density and lipid profile in Chinese women. Clin Interv Aging 2020; 15: 1649−1664.
Wang X, Jiang L, Shao X. Association analysis of insulin resistance and osteoporosis risk in Chinese patients with T2DM. Ther Clin Risk Manag 2021; 17: 909−916.
Zhuo M, Chen Z, Zhong ML, et al. Association of insulin resistance with bone mineral density in a nationwide health check-up population in China. Bone 2023; 170: 116703.
Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 2014; 25: 1439−1443.
Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr Metab 2014; 65: 205−210.
Mun SH, Jastrzebski S, Kalinowski J, et al. Sexual dimorphism in differentiating osteoclast precursors demonstrates enhanced inflammatory pathway activation in female cells. J Bone Miner Res 2021; 36: 1104−1116.
Kodrič K, Zupan J, Kranjc T, et al. Sex-determining region Y (SRY) attribute to gender differences in RANKL expression and incidence of osteoporosis. Exp Mol Med 2019; 51: 1−16.
Tabassum R, Ruotsalainen S, Ottensmann L, et al. Lipidome- and genome-wide study to understand sex differences in circulatory lipids. J Am Heart Assoc 2022; 11: e027103.
Karr S. Epidemiology and management of hyperlipidemia. Am J Manag Care 2017; 23: S139−S148.
Clynes MA, Harvey NC, Curtis EM, et al. The epidemiology of osteoporosis. Br Med Bull 2020; 133: 105−117.
Kan B, Zhao Q, Wang L, et al. Association between lipid biomarkers and osteoporosis: a cross-sectional study. BMC Musculoskelet Disord 2021; 22: 759.
Zhao X, Sun J, Xin S, et al. Correlation between blood lipid level and osteoporosis in older adults with type 2 diabetes mellitus: a retrospective study based on inpatients in Beijing, China. Biomolecules 2023; 13: 616.
Cheng XG, Yang DZ, Zhou Q, et al. Age-related bone mineral density, bone loss rate, prevalence of osteoporosis, and reference database of women at multiple centers in China. J Clin Densitom 2007; 10: 276−284.
Salamat MR, Salamat AH, Janghorbani M. Association between obesity and bone mineral density by gender and menopausal status. Endocrinol Metab (Seoul) 2016; 31: 547−558.
Fox KM, Tai MH, Kostev K, et al. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol 2018; 107: 380−388.
Inglin L, Lavikainen P, Jalkanen K, et al. LDL-cholesterol trajectories and statin treatment in Finnish type 2 diabetes patients: a growth mixture model. Sci Rep 2021; 11: 22603.
Yan Y, Li S, Liu Y, et al. Associations between life-course lipid trajectories and subclinical atherosclerosis in midlife. JAMA Netw Open 2022; 5: e2234862.
Yu H, Li Y, Tao L, et al. Trajectories of lipid profile and risk of carotid atherosclerosis progression: a longitudinal cohort study. Nutrients 2022; 14: 3243.
Trimarco V, Izzo R, Gallo P, et al. Long-lasting control of LDL cholesterol induces a 40% reduction in the incidence of cardiovascular event: new insights from a 7-year study. J Pharmacol Exp Ther 2023; 388: 742−747.
Anagnostis P, Florentin M, Livadas S, et al. Bone health in patients with dyslipidemias: an underestimated aspect. Int J Mol Sci 2022; 23: 1639.
Wang B, Wang H, Li Y, et al. Lipid metabolism within the bone micro-environment is closely associated with bone metabolism in physiological and pathophysiological stages. Lipids Health Dis 2022; 21: 5.
Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000; 355: 2218−2219.
Qin Y, O Santos H, Khani V, et al. Effects of dehydroepiandrosterone (DHEA) supplementation on the lipid profile: a systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 2020; 30: 1465−1475.
Lee S, Seo DH, Kim KM, et al. Contingent association between the size of the social support network and osteoporosis among Korean elderly women. PLoS One 2017; 12: e0180017.
Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 2014; 383: 146−155.